Home › Research › Caregiving
Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases
Gomperts SN, Locascio JJ, Makaretz SJ, Schultz A, Caso C, Vasdev N, Sperling R, Growdon JH et al.. JAMA neurology, 2016-11-01
Topic: Brain proteins, microglia and lab models
Plain-language summary
Twenty-four patients with Lewy body disease (7 DLB, 8 PD-impaired, and 9 PD-normal) underwent multimodal brain imaging, cognitive testing, and neurologic evaluation, and imaging measures were compared with those of an independently acquired group of 29 controls with minimal brain amyloid burden as measured with carbon 11-labeled Pittsburgh Compound B ([11C]PiB) positron emission tomography (PET). Results In patients with DLB, cortical [18F]AV-1451 uptake was highly variable and greater than in the controls, particularly in the inferior temporal gyrus and precuneus. For DLB and PD-impaired patients, greater [18F]AV-1451 uptake in the inferior temporal gyrus and precuneus was associated with increased cognitive impairment as measured with the MMSE and the Clinical Dementia Rating scale sum-of-boxes score. When present, tau deposition is associated with cognitive impairment. These findings support a role for tau copathology in the Lewy body diseases.
What this study adds
Evidence grade: Low
This is a cross-sectional study. In 24 patients with Lewy body disease, greater tau tracer uptake in certain brain regions was associated with increased cognitive impairment. This is a small cross-sectional imaging study in Lewy body diseases, not Alzheimer's disease, and it tests no treatment, cure, or prevention.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Gomperts, S. N., Locascio, J. J., Makaretz, S. J., Schultz, A., Caso, C., Vasdev, N., et al. (2016). Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases. JAMA neurology. https://doi.org/10.1001/jamaneurol.2016.3338
Vancouver
Gomperts SN, Locascio JJ, Makaretz SJ, Schultz A, Caso C, Vasdev N, et al. Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases. JAMA neurology. 2016. doi:10.1001/jamaneurol.2016.3338. PMID: 27654968.
BibTeX
@article{gomperts2016-27654968,
author = {Gomperts, S. N. and Locascio, J. J. and Makaretz, S. J. and Schultz, A. and Caso, C. and Vasdev, N. and Sperling, R. and Growdon, J. H. and others},
title = {{Tau Positron Emission Tomographic Imaging in the Lewy Body Diseases}},
journal = {JAMA neurology},
year = {2016},
doi = {10.1001/jamaneurol.2016.3338},
pmid = {27654968},
url = {https://doi.org/10.1001/jamaneurol.2016.3338}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Twenty-four patients with Lewy body disease (7 DLB, 8 PD-impaired, and 9 PD-normal) underwent multimodal brain imaging, cognitive testing, and neurologic evaluation, and imaging measures were compared with those of an independently acquired group of 29 controls with minimal brain amyloid burden as measured with carbon 11-labeled Pittsburgh Compound B ([11C]PiB) positron emission tomography (PET).
- Results In patients with DLB, cortical [18F]AV-1451 uptake was highly variable and greater than in the controls, particularly in the inferior temporal gyrus and precuneus.
- For DLB and PD-impaired patients, greater [18F]AV-1451 uptake in the inferior temporal gyrus and precuneus was associated with increased cognitive impairment as measured with the MMSE and the Clinical Dementia Rating scale sum-of-boxes score.
- When present, tau deposition is associated with cognitive impairment.
- These findings support a role for tau copathology in the Lewy body diseases.
Why it matters
In 24 patients with Lewy body disease, greater tau tracer uptake in certain brain regions was associated with increased cognitive impairment. This is a small cross-sectional imaging study in Lewy body diseases, not Alzheimer's disease, and it tests no treatment, cure, or prevention.
New to this subject? Start with our plain-English guide: Caregiving →
Study details
- Study designcross-sectional
- Evidence strengthLow
How this study scored 55/100
Published in a leading specialty journal, and it is a snapshot of people at one point in time. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (JAMA neurology) |
| Journal's citation record | 2 / 4 | JAMA Neurology: journal h-index 235 (OpenAlex, 2026-10-29) |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2016 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 228 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 19.0 citations a year over 12 year(s) since 2016 |
| Impact for its field and year | 5 / 6 | Cited 22.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 24 other studies in this library |
| Still being cited | 2 / 4 | Cited 46 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Keith A. Johnson: h-index 127 (OpenAlex, whole career) |
| Institution's track record | 3 / 3 | Harvard University: institution h-index 3,235 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 27654968) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 55 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1001/jamaneurol.2016.3338
- PubMed: 27654968
- Original source →
- Free full text: PubMed Central →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 22.
Later studies that cite this one
24 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Caregiving from nearby years
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.